Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period.
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor- and Metformin-Associated Euglycemic Diabetic Ketoacidosis and Lactic Acidosis Leading to Refractory Acute Kidney Injury: Successful Management With Hemodialysis.
Yoshida N, Tanaka T, Suzuki Y, Sakurai H, Takahashi S, Hitaka M, Ishii S, Okuda J, Yamazaki K, Ohashi Y.
Cureus. 2025 Mar 22;17(3):e80989. doi: 10.7759/cureus.80989. eCollection 2025 Mar.
PMID:40264625
Factors related to lactic acidosis observed in diabetic ketoacidosis and its effect on the treatment process.
Bahçebaşı S, Şimşek Y.
Endocrine. 2025 Oct;90(1):149-156. doi: 10.1007/s12020-025-04377-7. Epub 2025 Aug 7.
PMID:40773090
Acute Metabolic Complications in Diabetes.
Rewers A.
In: Cowie CC, Casagrande SS, Menke A, Cissell MA, Eberhardt MS, Meigs JB, Gregg EW, Knowler WC, Barrett-Connor E, Becker DJ, Brancati FL, Boyko EJ, Herman WH, Howard BV, Narayan KMV, Rewers M, Fradkin JE, editors. Diabetes in America. 3rd edition. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018 Aug. CHAPTER 17.
PMID:33651551
Pharmacological treatment of type 2 diabetes in elderly patients with heart failure: randomized trials and beyond.
Sciacqua A, Succurro E, Armentaro G, Miceli S, Pastori D, Rengo G, Sesti G.